VERV - Verve Therapeutics, Inc. Stock Price, Fair Value and News

$4.59+0.08 (+1.77%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

VERV Price Action

Last 7 days

50.5%

Last 30 days

-20.4%

Last 90 days

-25.2%

Trailing 12 Months

-31.9%

VERV RSI Chart

VERV Valuation

Market Cap

407.6M

Price/Earnings (Trailing)

-2.05

Price/Sales (Trailing)

12.61

EV/EBITDA

-1.23

Price/Free Cashflow

-2.52

VERV Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

VERV Fundamentals

VERV Revenue

Revenue (TTM)

32.3M

Rev. Growth (Yr)

154.28%

Rev. Growth (Qtr)

90.53%

VERV Earnings

Earnings (TTM)

-198.7M

Earnings Growth (Yr)

-3.48%

Earnings Growth (Qtr)

0.2%

VERV Profitability

EBT Margin

-613.51%

Return on Equity

-40.27%

Return on Assets

-30.69%

Free Cashflow Yield

-39.61%

VERV Investor Care

Shares Dilution (1Y)

32.80%

Diluted EPS (TTM)

-2.35

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	16.0M	20.6M	24.4M	32.3M
2023	4.4M	6.8M	9.3M	11.8M
2022	0	0	0	1.9M

Get all data in R, Python etc through our Historical Stock Data APIs

About Verve Therapeutics, Inc.

Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

CEO	Dr. Sekar Kathiresan M.D.
WEBSITE	vervetx.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	204

Verve Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Verve Therapeutics, Inc.? What does VERV stand for in stocks?

VERV is the stock ticker symbol of Verve Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Verve Therapeutics, Inc. (VERV)?

As of Thu Apr 17 2025, market cap of Verve Therapeutics, Inc. is 407.57 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VERV stock?

You can check VERV's fair value in chart for subscribers.

Is Verve Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether VERV is over valued or under valued. Whether Verve Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Verve Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VERV.

What is Verve Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Apr 17 2025, VERV's PE ratio (Price to Earnings) is -2.05 and Price to Sales (PS) ratio is 12.61. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VERV PE ratio will change depending on the future growth rate expectations of investors.